Another limitation that requires addressing is the absence of information regarding specific diabetes treatment (such as SGLT2 inhibitors that aside from diabetes mellitus, can have other indications including heart failure) and diabetic complications at the time of inclusion when a diagnosis of diabetes was present. The gene discussed is SLC5A2; the disease is heart failure.